Compare Colgate-Palmolive Company (CL) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Colgate-Palmolive Company vs DexCom, Inc. — how do they compare? Colgate-Palmolive Company trades at $92.31 (market cap $73.59B), while DexCom, Inc. trades at $88.99 (market cap $33.79B). The key difference: Colgate-Palmolive Company is far larger — about 2.2× DexCom, Inc.'s market cap, and Colgate-Palmolive Company pays a 2.3% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| CL | DXCM | |
|---|---|---|
Market Cap | $73.59B | $33.79B |
Sector | Consumer Staples | Health |
52-Week High | $99.14 | $89.53 |
52-Week Low | $74.98 | $54.84 |
Enterprise Value | $80.07B | $33.24B |
Dividend Yield | 2.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Colgate-Palmolive (CL) trades at $93.15, down 0.13% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 EPS of $0.99, beating estimates, with 4.9% sales growth driven by emerging markets. However, North American weakness persists, and valuation ratios like P/E of 36.34 and P/B of 311.81 appear elevated. Cash flow remains positive, and a dividend of $0.53 is scheduled for August 2026.
Outlook is mixed: strong brand presence and dividend sustainability support the stock, but high valuation and domestic challenges pose risks. Analyst consensus price target is $99.10, implying modest upside, with 42% buy ratings. Key risks include competitive pressures and margin compression from inflation.
DexCom (DXCM) trades at $87.65, up 3.42% today and near its 52-week high, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.66B in 2025, with net income reaching $836.30M and a 20.12% net margin. Recent Q2 2026 earnings beat expectations with $0.70 EPS, and the company raised full-year guidance, reflecting robust demand for its continuous glucose monitoring systems.
The outlook remains positive given consistent earnings beats, margin expansion, and analyst consensus favoring a buy rating with a $88.65 price target. Key risks include competitive pressures in medical devices and potential regulatory scrutiny, but growth drivers like G7 adoption and international expansion support upside potential for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Colgate-Palmolive Company
Since its founding in 1806, Colgate-Palmolive has grown to become a leading global consumer product company. In addition to its namesake oral care line, the firm manufactures shampoos, shower gels, deodorants, and home care products that are sold in over 200 countries (international sales account for about 70% of its consolidated total, including approximately 45% from emerging regions). It also owns specialty pet food maker Hill's, which sells its products through veterinarians and specialty pet retailers.
Read more on CL →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
